- VIVUS Reports Third Quarter 2014 Financial Results
- VIVUS Announces Qsymia Presentations at Obesity Week 2014
- VIVUS Announces Date of Third Quarter 2014 Update and Financial Results Conference Call
- Newly Published Data Highlight the Effects of Weight Loss With Qsymia in Type 2 Diabetes
- VIVUS and Auxilium Announce FDA Approval of STENDRA sNDA; STENDRA Now First and Only Oral Erectile Dysfunction Treatment Approved to Be Taken Approximately 15 Minutes Before Sexual Activity
Latest EventsThere are currently no upcoming events
A Growing Pipeline
VIVUS is developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, sleep apnea and sexual health.